Adaptive Biotechnologies Company Insiders

ADPT Stock  USD 8.24  0.48  5.50%   
Adaptive Biotechnologies employes about 790 people. The company is managed by 29 executives with a total tenure of roughly 142 years, averaging almost 4.0 years of service per executive having 27.24 employees per reported executive. Break down Adaptive Biotechnologies management performance can provide insight into the firm performance. Note, employee sentiment is becoming a valuable factor that investors use to determine the amount of risk that may be associated with Adaptive Biotechnologies future performance.
Check out Trending Equities. For more information on how to buy Adaptive Stock please use our How to Invest in Adaptive Biotechnologies guide.
Chad Robins  CEO
President CEO, Co-Founder
Thomas Hall  Chairman
Chairman and CEO
Richard Covert  Chairman
Chairman of the Board

Adaptive Biotechnologies Return on Sales


Adaptive Biotechnologies Management Team Effectiveness

Adaptive Biotechnologies has return on total asset (ROA) of (0.1395) % which means that it has lost $0.1395 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (0.3752) %, meaning that it created substantial loss on money invested by shareholders. Adaptive Biotechnologies management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. Return on Investment is likely to gain to 17.98 in 2023, whereas Return on Average Assets are likely to drop (0.26)  in 2023. Total Liabilities is likely to drop to about 349.6 M in 2023. Current Liabilities is likely to drop to about 101.3 M in 2023

Adaptive Biotechnologies Quarterly Total Assets

856.62 Million

Issuance Purchase of Equity Shares is likely to gain to about 8.1 M in 2023, whereas Weighted Average Shares is likely to drop slightly above 124 M in 2023.

Adaptive Biotechnologies Workforce Comparison

Adaptive Biotechnologies Corp is rated fourth in number of employees category among related companies. The total workforce of Health Care industry is presently estimated at about 71,317. Adaptive Biotechnologies claims roughly 790 in number of employees contributing just under 2% to equities under Health Care industry.

Adaptive Biotechnologies Profit Margins

The company has Profit Margin (PM) of (1.08) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.07) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.07.

Adaptive Biotechnologies Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Adaptive Biotechnologies insiders, such as employees or executives, is commonly permitted as long as it does not rely on Adaptive Biotechnologies' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Adaptive Biotechnologies insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Adaptive Biotechnologies Benchmark Summation

Adaptive Biotechnologies Notable Stakeholders

An Adaptive Biotechnologies stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Adaptive Biotechnologies often face trade-offs trying to please all of them. Adaptive Biotechnologies' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Adaptive Biotechnologies' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Harlan RobinsCo-Founder, Chief Scientific OfficerProfile
Chad RobinsPresident CEO, Co-FounderProfile
Thomas HallChairman and CEOProfile
Richard CovertChairman of the BoardProfile
Nancy HillSenior Vice President General Manager - Research ProductsProfile
Frank WilliamsCFO, Executive Vice PresidentProfile
WillisSenior Vice President General Manager - Diagnostic ProductsProfile
Dean SchornoCFOProfile
Timothy FieldingCFO and TreasurerProfile
Graham CherringtonPres and COOProfile
Traci BowenSr. VP of HRProfile
Ronald TaylorIndependent DirectorProfile
Daniel RosenbergDirectorProfile
Stephen MengertDirectorProfile
Gregory ScottIndependent DirectorProfile
Jeffery VenderIndependent DirectorProfile
Steven NapolitanoIndependent DirectorProfile
James MuzzarelliExecutive Medical DirectorProfile
Yi ZhouChief OfficerProfile
Ricardo MartinezChief Medical OfficerProfile
Mark AdamsChief OfficerProfile
Julie RubinsteinPresidentProfile
Andrew JordanChief Marketing OfficerProfile
Nitin SoodChief MRDProfile
Tycho PetersonChief OfficerProfile
Kyle PiskelPrincipal OfficerProfile
Karina CalzadillaVP RelationsProfile
MBA MBACEO CoFounderProfile
Christopher CarlsonFounderProfile

About Adaptive Biotechnologies Management Performance

The success or failure of an entity such as Adaptive Biotechnologies often depends on how effective the management is. Adaptive Biotechnologies management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Adaptive management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Adaptive management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for 2023
Return on Investment 16.67  17.98 
Return on Average Assets(0.23) (0.26) 
Return on Average Equity(0.40) (0.41) 
Return on Invested Capital(0.30) (0.32) 
Return on Sales(1.06) (1.14) 
The data published in Adaptive Biotechnologies' official financial statements usually reflect Adaptive Biotechnologies' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Adaptive Biotechnologies. For example, before you start analyzing numbers published by Adaptive accountants, it's critical to develop an understanding of what Adaptive Biotechnologies' liquidity, profitability, and earnings quality are in the context of the Life Sciences Tools & Services space in which it operates.
Please note, the presentation of Adaptive Biotechnologies' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Adaptive Biotechnologies' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Adaptive Biotechnologies' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Adaptive Biotechnologies Corp. Please utilize our Beneish M Score to check the likelihood of Adaptive Biotechnologies' management to manipulate its earnings.

Adaptive Biotechnologies Workforce Analysis

Traditionally, organizations such as Adaptive Biotechnologies use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Adaptive Biotechnologies within its industry.

Adaptive Biotechnologies Manpower Efficiency

Return on Adaptive Biotechnologies Manpower

Revenue Per Employee100.3K
Revenue Per Executive6.4M
Net Income Per Employee4K
Net Loss Per Executive6.9M
Working Capital Per Employee75.2K
Working Capital Per Executive2M
Today, most investors in Adaptive Biotechnologies Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Adaptive Biotechnologies' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's per employee growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Adaptive Biotechnologies per employee as a starting point in their analysis.

Net Income Per Employee


Adaptive Biotechnologies Net Income Per Employee is comparatively stable at the moment as compared to the past year. Adaptive Biotechnologies reported Net Income Per Employee of 3,715 in 2022

Revenue Per Employee


Adaptive Biotechnologies Revenue Per Employee is comparatively stable at the moment as compared to the past year. Adaptive Biotechnologies reported Revenue Per Employee of 102,505 in 2022
Check out Trending Equities. For more information on how to buy Adaptive Stock please use our How to Invest in Adaptive Biotechnologies guide. You can also try Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.

Complementary Tools for analysis

When running Adaptive Biotechnologies price analysis, check to measure Adaptive Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptive Biotechnologies is operating at the current time. Most of Adaptive Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Adaptive Biotechnologies' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Adaptive Biotechnologies' price. Additionally, you may evaluate how the addition of Adaptive Biotechnologies to your portfolios can decrease your overall portfolio volatility.
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
CEO Directory
Screen CEOs from public companies around the world
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Is Adaptive Biotechnologies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adaptive Biotechnologies. If investors know Adaptive will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adaptive Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
Revenue Per Share
Quarterly Revenue Growth
Return On Assets
Return On Equity
The market value of Adaptive Biotechnologies is measured differently than its book value, which is the value of Adaptive that is recorded on the company's balance sheet. Investors also form their own opinion of Adaptive Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Adaptive Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adaptive Biotechnologies' market value can be influenced by many factors that don't directly affect Adaptive Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adaptive Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine Adaptive Biotechnologies value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adaptive Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.